Akero Therapeutics (AKRO) stock surged 5.95% in intraday trading on Wednesday, buoyed by the company's successful equity raise and positive clinical trial results for its lead drug candidate.
On Tuesday, Akero Therapeutics announced the pricing of an upsized public offering, raising $350 million through the sale of approximately 5.3 million shares and pre-funded warrants to purchase an additional 2 million shares. The offering was well-received by investors, signaling confidence in the company's financial position and growth prospects.
Moreover, the stock's rally was further fueled by promising results from a study on Akero's lead drug candidate, efruxifermin. The drug demonstrated its ability to reverse scarring and improve liver health in patients with a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH). This positive development highlighted the potential of efruxifermin and bolstered investor optimism in the company's pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.